#Sweden #Stockholm #ColdZyme #Enzymatica #Research Studies

Enzymatica AB Holds Press Briefing on ColdZyme Research Results

Enzymatica AB is set to conduct a significant digital press briefing on March 5, 2025, linking it with the launch of results from two independent studies concerning their innovative product, ColdZyme. This press event highlights the advancements in understanding how ColdZyme addresses the fundamental causes of respiratory infections, which is a pressing health concern for many.

Event Details
The digital press briefing will take place from 13:00 to 15:00 (CET), with the initial portion dedicated to renowned researchers presenting their findings and addressing questions from attendees. This will provide a unique opportunity for media representatives to gain insight into the most recent scientific developments involving ColdZyme. Following the researchers' presentations, Enzymatica's CEO, Claus Egstrand, alongside Chairman Bengt Baron, will offer an overview of the company's perspective and future directions. They will also engage in a Q&A session, addressing inquiries from the press.

Research Findings
The studies, which were rigorously conducted and peer-reviewed, demonstrated that ColdZyme yields positive effects in reducing sick days and alleviating symptoms associated with respiratory infections. These findings represent a significant improvement in understanding how ColdZyme can be a valuable tool for individuals at risk of respiratory ailments and could revolutionize approaches to respiratory health.

How to Participate
The event will be broadcast live, allowing journalists from various outlets the chance to participate in real-time discussions and ask questions directly. Interested parties can secure their place in the event by registering through the provided link. This ensures that participants can stay up-to-date with the latest in health science and product efficacy pertaining to ColdZyme.

For those who want to delve deeper into the preliminary results and scientific backing of ColdZyme, a linked article from The Journal of Physiology offers comprehensive insights into the research methodologies employed and the subsequent findings. This publication solidifies the credibility of the findings shared in the upcoming press briefing.

Contact Information
For additional queries or information regarding the press briefing and ENZYMATICA's research initiatives, interested media personnel can reach out to Anja Tragardh in the Corporate Communications division. Contact details and further instructions for inquiry submission will be provided after registering for the event.

In summary, Enzymatica AB is taking an important step in enhancing public knowledge surrounding respiratory health and the role of ColdZyme in alleviating issues associated with respiratory infections. This press briefing marks a vital engagement point for media, researchers, and public health advocates.